Loading...
Loading...
BioCryst
Pharmaceuticals, Inc.
BCRX today announced that the
randomized, placebo-controlled, Phase 1 clinical trial of
orally-administered BCX4161
in healthy volunteers successfully met all of its objectives. The
safety, tolerability, drug exposure and on-target kallikrein inhibition
results of this Phase 1 trial strongly support advancing the development
program into a Phase 2a study in hereditary angioedema (HAE) patients.
Overall, 87 healthy volunteers completed the study; 30 received a single
dose of BCX4161 from 50 mg up to 1000 mg, 40 subjects received 100 mg,
200 mg, 400 mg, or 800 mg BCX4161 every eight hours for seven days and
17 received placebo.
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in